#EULAR2021 LB0001. Mavrilimumab (blocks GM-CSF alpha) phase2 trial in non-vented patients w/ #COVID19 : ⭐️⬇️ mortality and ventilation at day 29 ⭐️61% reduction in death (HR 0.39) ⭐️No drug related SAEs, no dose-related AEs @Rheumnow https://t.co/9UOi3xF7Re